{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:46:49Z","timestamp":1768888009926,"version":"3.49.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,24]]},"abstract":"<jats:p>The aim of this study was to evaluate the clinical benefits and outcomes of adjuvant radiation therapy on adrenocortical carcinoma (ACC) patients. All patients with ACC that were reported between 2010 and 2015 were identified from the Surveillance, Epidemiology, and End Results database. A forward-stepwise Cox proportional hazards regression was used to identify independent risk factors. A new nomogram was created to predict overall and cancer-free survival probabilities at 1, 3, and 5 years for ACC patients. The concordance index, the area under the receiver operating characteristic curve, calibration curves, and decision curve analysis were used to validate the accuracy and reliability of the model. A total of 426 ACC patients were enrolled in this study, of which 84 (19.7%) cases underwent adjuvant radiation therapy (RT). Six factors (age, T stage, type of surgery, radiation, and bone and liver metastases) were significantly related to overall survival (OS) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Five factors (T stage, type of surgery, radiation, and bone and liver metastases) were significantly related to cancer-specific survival (CSS) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). A nomogram for OS and CSS was constructed. The area under the receiver operating characteristic curve values for 1-, 3-, and 5-year OS were 0.85, 0.818, and 0.814, respectively, and for CSS, they were 0.839, 0.803, and 0.796, respectively. C-indices were 0.756 and 0.749 for OS and CSS, respectively, indicating that the nomograms for OS and CSS had satisfactory discriminative power. A good consistency between the observed and the predicted survival was found in the calibration curves, and the nomogram has a good net clinical benefit, which is presented in the decision curve analysis curves. Our study demonstrates that adjuvant RT can produce a significant improvement in survival outcomes for ACC patients and suggests that adjuvant RT should routinely be applied in ACC patients.<\/jats:p>","DOI":"10.1097\/md.0000000000041313","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T23:00:44Z","timestamp":1737759644000},"page":"e41313","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant radiation improves survival outcomes in adrenocortical carcinoma: A population-based study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9093-3551","authenticated-orcid":false,"given":"Kunming","family":"Zhan","sequence":"first","affiliation":[{"name":"Department of Urology, Xiang Yang No.1 People\u2019s Hospital Affiliated Hospital of Hubei University of Medicine, Xiangyang, China"},{"name":"Department of Urology, Shiyan People\u2019s Hospital, Jinzhou Medical University Training Base, Shiyan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianguo","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiang Yang No.1 People\u2019s Hospital Affiliated Hospital of Hubei University of Medicine, Xiangyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Urology, Shiyan People\u2019s Hospital, Jinzhou Medical University Training Base, Shiyan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250124","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993.","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"key":"R2-20250124","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.surg.2011.09.030","article-title":"Recommendation for standardized surgical management of primary adrenocortical carcinoma.","volume":"152","author":"Gaujoux","year":"2012","journal-title":"Surgery"},{"key":"R3-20250124","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00268-021-05957-0","article-title":"Adrenal surgery for synchronously metastatic adrenocortical carcinoma: a population-based analysis.","volume":"45","author":"Wu","year":"2021","journal-title":"World J Surg"},{"key":"R4-20250124","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"R5-20250124","doi-asserted-by":"crossref","first-page":"636","DOI":"10.14740\/jocmr3503w","article-title":"The characteristics and trends in adrenocortical carcinoma: a United States population based study.","volume":"10","author":"Sharma","year":"2018","journal-title":"J Clin Med Res"},{"key":"R6-20250124","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","article-title":"Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.","volume":"25","author":"Icard","year":"2001","journal-title":"World J Surg"},{"key":"R7-20250124","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma.","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-20250124","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MED.0000000000000056","article-title":"Practical treatment using mitotane for adrenocortical carcinoma.","volume":"21","author":"Terzolo","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R9-20250124","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00104-016-0288-9","article-title":"Kein Vorteil f\u00fcr adjuvante Mitotanetherapie nach Adrenalektomie beim Nebennierenrindenkarzinom [Adjuvant mitotane treatment after adrenalectomy is not beneficial for adrenocortical carcinoma].","volume":"87","author":"Dralle","year":"2016","journal-title":"Chirurg"},{"key":"R10-20250124","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2005-2639","article-title":"Clinical review: adrenocortical carcinoma: clinical update.","volume":"91","author":"Allolio","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20250124","doi-asserted-by":"crossref","first-page":"e6741","DOI":"10.1097\/MD.0000000000006741","article-title":"The efficacy of radiation therapy in adrenocortical carcinoma: a propensity score analysis of a population-based study.","volume":"96","author":"Luo","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R12-20250124","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1245\/s10434-018-6510-x","article-title":"Adjuvant radiation is associated with improved survival for select patients with non-metastatic adrenocortical carcinoma.","volume":"25","author":"Nelson","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R13-20250124","doi-asserted-by":"crossref","first-page":"1308231","DOI":"10.3389\/fendo.2023.1308231","article-title":"Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma.","volume":"14","author":"Wu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Supplement","key":"R14-20250124","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.4103\/jcrt.JCRT_996_15","article-title":"Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: a systematic review of observational studies and meta-analysis.","volume":"15","author":"Viani","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R15-20250124","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","article-title":"Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.","volume":"92","author":"TSabolch","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20250124","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma.","volume":"104","author":"Gharzai","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20250124","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/08941939.2021.1968981","article-title":"Nomograms for individualized evaluation of prognosis in adrenocortical carcinomas for the elderly: a population-based analysis.","volume":"35","author":"Wang","year":"2022","journal-title":"J Invest Surg"},{"key":"R18-20250124","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R19-20250124","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejca.2009.12.007","article-title":"The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.","volume":"46","author":"Lughezzani","year":"2010","journal-title":"Eur J Cancer"},{"key":"R20-20250124","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"key":"R21-20250124","doi-asserted-by":"crossref","first-page":"e2084","DOI":"10.1210\/clinem\/dgae047","article-title":"The European Network for the Study of Adrenal Tumors staging system (2015): a United States validation.","volume":"109","author":"Jannello","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20250124","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.6004\/jnccn.2021.7035","article-title":"Benefit of postoperative radiotherapy for patients with nonmetastatic adrenocortical carcinoma: a population-based analysis.","volume":"19","author":"Wu","year":"2021","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T23:00:51Z","timestamp":1737759651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041313","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}